Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) announced that its subsidiaries, Tianjin Peace Pharmaceutical Co., Ltd. and Hubei Tian Pharmaceutical Co., Ltd., participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1 - The subsidiaries involved in the procurement are Tianjin Peace Pharmaceutical and Hubei Tian Pharmaceutical [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1]

Core Viewpoint - The company announced that its subsidiaries participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1: Procurement Participation - The subsidiaries of the company, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd. and Hubei Tianjin Pharmaceutical Co., Ltd., are involved in the national centralized drug procurement [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1] Group 2: Financial Impact - The total projected sales revenue from the selected products for the year 2024 is approximately 95.16 million yuan, accounting for 2.96% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue from these products is approximately 22.08 million yuan, representing 0.99% of the company's revenue for that period [1]